Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Elderly patients of pancreatic ductal adenocarcinoma (PDAC) suffer from worse health-related quality of life (HRQoL), particularly in terms of physical health status, a recent study has found.

Researchers enrolled 128 elderly adults with PDAC (mean age, 76.2±6.4 years; 54.7 percent female) and 512 matched controls (mean age, 76.2±6.4 years; 54.7 percent female) who had no history of cancer. The Short Form 36 (SF-36) and the Veterans-RAND-12 (VR-12) were used to measure HRQoL and the corresponding physical (PCS) and mental (MCS) component summary scores.

Patients and controls were generally comparable in terms of the total number of comorbidities (p=0.4), though cancer patients were more likely to have diabetes (p<0.001), while musculoskeletal diseases were more common in controls (p=0.03).

However, independently of such comorbidities, PDAC patients reported significantly lower mean PCS than healthy controls (29.3±1.2 vs 36.3±0.7; p<0.001). MCS scores were better than PCS, but patients continued to suffer worse HRQoL in this domain than controls (44.8±1.1 vs 49.0±0.7; p<0.001). The resulting adjusted mean differences were 7.0 and 5.1 for PCS and MCS, respectively.

Notably, however, the total number of comorbidities and system-level comorbidities nevertheless appeared to have a negative impact on PCS and MCS in controls.

“The results of this analysis emphasize the need for more attention on the HRQoL of older patients with PDAC,” the researchers said. There have been preliminary investigations regarding possible interventions that may help with this problem, including early supportive care psychotherapy, psychiatric means and symptom management. However, further studies are needed to draw definite conclusions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.